Suraksha Diagnostic Records Healthy Growth, Driven by Increased Test Volumes and Realizations in FY26
Kolkata, 21 May 2026: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and full year ended 31 March 2026. The company reported robust financial performance, noting that its total income grew by 25% year-on-year and EBITDA grew by 26% year-on-year in Q4FY26.The company’s financial data for the full fiscal year and the fourth quarter paints a picture of consistent growth and network expansion.
FY26 Financial Performance Snapshot
Analyzing the key financial metrics reveals significant year-on-year growth across the board.| Particulars | Q4 FY26 | Q4 FY25 | Y-o-Y | FY26 | FY25 | Y-o-Y |
|---|---|---|---|---|---|---|
| Total Income (₹ million) | 821.97 | 659.12 | 24.7% | 3135.78 | 2559.39 | 22.5% |
| EBTIDA (₹ million) | 251.55 | 200.05 | 25.7% | 985.58 | 850.88 | 15.8% |
| EBTIDA Margin (%) | 30.9% | 30.7% | 31.8% | 33.8% | ||
| PAT (₹ million) | 61.59 | 71.71 | -14.1% | 314.04 | 309.78 | 1.4% |
| PAT Margin (%) | 7.6% | 11.0% | 10.1% | 12.3% |
Key Operational Highlights
Operational metrics underscore the growth, particularly in patient volume and tests conducted.| Particulars | Q4 FY26 | Q4 FY25 | Y-o-Y | FY26 | FY25 | Y-o-Y |
|---|---|---|---|---|---|---|
| Total tests (# million) | 1.97 | 1.82 | 8.2% | 8.16 | 6.68 | 22.0% |
| Total Patients (# million) | 0.3 | 0.29 | 1.7% | 1.37 | 1.19 | 14.9% |
| Tests per patient (#) | 6.57 | 6.17 | 6.4% | 5.95 | 5.6 | 6.2% |
| Average Revenue per test (₹) | 421 | 356 | 15.6% | 381 | 377 | 0.9% |
| Average Revenue per patient (₹) | 2706 | 2201 | 23% | 2264 | 2113 | 7.1% |
Management Commentary on Growth Strategy
Mrs. Ritu Mittal, Joint Managing Director & CEO, commented on the results, stating that the company concluded FY26 on a strong note, driven by sustained momentum in network expansion and improving market presence.She noted that the EBITDA margin reflects investments into newly launched centers and expansion initiatives. The company's centers older than two years continue to demonstrate resilience, maintaining an EBITDA margin of 36-37%. The focus remains on "Investing for Scale: Short-term Compression for Longterm Value Creation."
During FY26, Suraksha Diagnostic expanded its footprint significantly by adding 2 hubs, 11 spoke centers, and 4 PPP locations, thereby strengthening its reach and accessibility across key markets. Furthermore, the recently launched genomic lab performed very well.
Looking ahead, the company remains committed to achieving higher utilization across new centers, enhancing operational efficiencies, and delivering sustainable growth to create long-term value for its shareholders.
SURAKSHA Stock Price Movement
On Thursday, Suraksha Diagnostic Limited shares rallied 5.56%, closing at ₹322 after a strong move of ₹16.95. The stock was supported by considerable activity, seeing a total trading volume of 173,542 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.